The Science of Small Clinical Trials
|
|
- Brenda Wood
- 6 years ago
- Views:
Transcription
1 The Science of Small Clinical Trials Introduction to Small Clinical Trials an Industry Perspective Simon Day, PhD
2 Confucius (allegedly) When it is obvious that the goals cannot be reached, don t adjust the goals, adjust the action steps. 2
3 Me a man of numbers(?) One pharmaceutical industry maybe with pharma/biotech sub-groups devices another subgroup, or are they different? Many sizes Many philosophies Many strategic directions One (?) purpose 3
4 The dirty word Pharma and device companies are there to make money for shareholders I reconcile this with The only way to make money, is to make good medicines, that help patients, and for which those patients (or the payers!) are therefore willing to pay And if I make lots of good medicines and lots of money, I can plough that back into research to find lots more medicines, and make even more money! 4
5 Industry Perspective 5
6 Varieties Of companies, approaches, and problems Big companies Stuck in mind-set of non-orphans SOPs inappropriate and infelxible Committees all over the place Databases too big and clumsy Rigid on (apparent) regulatory requirements But very good (sometimes) at turning in NDAs 6
7 Varieties Of companies, approaches, and problems Small (orphan) companies Stuck in mind-set of orphans SOPs not so well thought out Committees lack of clear structure Databases ad hoc, inefficient, etc. Naïve to regulatory requirements Lack of experience at turning in NDAs 7
8 Varieties Of companies, approaches, and problems Niche (orphan) companies Keep clear focus on orphans SOPs fit for purpose Committees fit for purpose Databases fit for purpose Experienced in regulatory requirements and options Good (sometimes) at turning in NDAs 8
9 Data sources Roche Ethics Committee (IRB) Friends and colleagues (EU) regulatory experience ICORD contacts Science of Small Clinical Trials (past years) Note, some examples not licensed, or uses discussed outside approved label 9
10 Example 1 Cystic Fibrosis Rare disease (of course) In this situation the best that can be achieved is an uncontrolled study of N=100. No justification of why 10
11 Example 2 Cystic Fibrosis Rare disease (of course) We know this is really stretching the limits of acceptability, but we plan to do a study of n 1 =80 patients on active and n 2 =40 patients on placebo. At least an acknowledgement and apology 11
12 Examples 1 and 2 Cystic Fibrosis Rare disease (of course) In this situation the best that can be achieved is an uncontrolled study of N=100. Meeting 9:30 11:00 We know this is really stretching the limits of acceptability, but we plan to do a study of n 1 =80 patients on active and n 2 =40 patients on placebo. Meeting 11:00 12:30 On the same day! 12
13 Example 3 bone marrow disorder Rare disease (of course) Two obvious sub-groups Not enough patients to do one (or more!) trial in each subgroup (maximum reasonable N 240) Run one study, with interim analysis to potentially drop one subgroup if no effect ( adaptive design ) If a subgroup is dropped, continue recruitment in the other subgroup, up to N=240 13
14 Example 4 cancer of blood cells Rare disease (of course) N 650; largest ever trial in this indication Primary endpoint, overall survival, P 0.10 Median survival 5 8 months Secondary endpoint, PFS, P<0.001 Longer follow-up of OS P=0.03 Median survival 5 8 months Don t file too much risk of failure / company image We ve used up all our alpha (i.e. 5% alpha) 14
15 Example 5 inflammation of arteries Rare disease (of course) Placebo controlled trial Sample size planned, N=200 Number of centres 120 Number of pages in protocol 120 By the way, there s another Phase II exploratory study of 27 patients being conducted in 1 centre 15
16 Example 6 inherited metabolic disease Rare disease (of course) Primary endpoint, 6 minute walk test Primary analysis, all patients Additional primary analysis(?) 2 well defined subgroups, because Treatment not expected to benefit all patients on the 6 minute walk test, so Why is that their primary endpoint? Alternative primary endpoint could be discussed 16
17 One Pharmaceutical Industry But very varied Many sizes Many philosophies Many strategic directions Some consistently make good decisions but don t always succeed Some consistently make bad decisions and sometimes get lucky (or rescued!) 17
Statistical Challenges: Designs for clinical trials with limited patient populations
Statistical Challenges Statistical Challenges: Designs for clinical trials with limited patient populations Simon Day, PhD simon.day@ctct-ltd.co.uk 1 Conflicts of interest (sorry!) 2 What do statisticians
More informationMulti-Regional Studies and Bridging Studies. Simon Day, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-nCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationStem Cell Uses and FDA Regulation
Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware
More informationAn Introduction to Clinical Research and Development
Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is
More informationLearning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationGene Therapy and Ethics: the Patient View. A tool for public dialogue
Gene Therapy and Ethics: the Patient View A tool for public dialogue Colofon This brochure has been developed by the European Genetic Alliances' Network EGAN. You are allowed to download, print or copy
More informationEthical approaches to Innovation in Global Health
Georg Marckmann Institute of Ethics, History and Theory of Medicine Ethical approaches to Innovation in Global Health World Health Summit Satellite Event Innovation in Health: The contribution of biologic
More informationEarly access or speed kills? A payer s perspective
Dürfen lebenswichtige Medikamente Early access or speed kills? A payer s perspective Health as the real winner: Presidency Conference on Options to Provide Better Medicines for All Sofia,06.03.2018, Director
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationClinical Trials: What You Need to Know
Clinical Trials: What You Need to Know Knowing all you can about clinical trials can help you feel better when deciding whether or not to take part in one. This guide addresses many basic questions and
More informationInterim Analysis of Randomized Clinical Trials. David L DeMets, PhD
Interim Analysis of Randomized Clinical Trials David L DeMets, PhD Need for Data Monitoring Phase I Trials (dose) Monitoring usually at local level Phase II Trials (activity) Most monitoring at local level
More informationEisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency
Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency This is not an official PMDA guidance or policy statement. No official support or endorsement by the PMDA is intended
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationIncentives and Regulatory Considerations in Orphan Drug/Medical Device Development - Situation in Japan -
Incentives and Regulatory Considerations in Orphan Drug/Medical Device Development - Situation in Japan - MHLW/PMDA, Japan Speaker: Hiroshi Takeda Reviewer, Office of New Drug III, PMDA 1 Disclaimer The
More informationIntroduction. Summary A LOOK AT CFTR MODULATORS FOR CYSTIC FIBROSIS JUNE 2018 TREATMENT OPTIONS CYSTIC FIBROSIS POLICY IMPLICATIONS
JUNE 2018 Introduction CYSTIC FIBROSIS Cystic fibrosis (CF) is a progressive genetic disease that affects many organ systems, though a significant proportion of its morbidity and mortality is associated
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationBuilding a Career in the Pharmaceutical Industry: Personal Reflections. Carlo Nalin, PhD Executive Director Novartis Oncology
Building a Career in the Pharmaceutical Industry: Personal Reflections Carlo Nalin, PhD Executive Director Novartis Oncology 2 Career Development: Personal Reflections C Nalin 5 April 2016 Cornell BEST
More informationCurrent Status and Perspectives of Placebo-controlled Studies
Provisional Translation (as of June 1, 2016) March 9, 2016 Current Status and Perspectives of Placebo-controlled Studies Subcommittee on Placebo-controlled Studies Kazuhiko Yamamoto, Chairperson Yoshihiro
More informationDeveloping Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationRegulatory scene setting - benefits and risks of seamless Phase II / III trials
Safeguarding public health Regulatory scene setting - benefits and risks of seamless Phase II / III trials Rob Hemmings, Statistics Unit Manager MHRA, London December 2007 Definitions we are concerned
More informationSubgroups along the development axis
Paper PD03 A dedicated Programming Group working in a pharmaceutical Modeling & Simulation organization Vincent Buchheit, Novartis, Basel, Switzerland 1. ABSTRACT Modeling and Simulation (M&S) emerges
More informationBasket, umbrella and platform trials: a regulatory perspective. Julia Saperia
Basket, umbrella and platform trials: a regulatory perspective Julia Saperia PSI webinar 18 th April 2018 Acknowledgments David Brown (MHRA, BSWP) Olivier Collignon (LIH, BSWP, EMA) Anja Schiel (NoMA,
More informationIntroduction to Adaptive Design Roger J. Lewis, MD, PhD
Introduction to Adaptive Design Roger J. Lewis, MD, PhD Financial Disclosures Berry Consultants, LLC Multiple clients U01 Support from National Institutes of Health/NINDS Food and Drug Administration AspenBio
More informationHEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE
HEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE NATASHA KEKRE, MD, MPH, FRCPC NOV 16, 2016 www.ohri.ca WHY THIS MATTERS TO ME I am a hematologist in Ottawa with 75% dedicated time for research
More informationRole of drug regulation (if any )
Health, Growth and Finance Brescia 17 th June 2016 Role of drug regulation (if any ) Presented by Guido Rasi Executive Director, European Medicines Agency An agency of the European Union Mandate of EMA
More informationNIMPs (v IMPs): Definitions and Practical Approaches
NIMPs (v IMPs): Definitions and Practical Approaches Esther Sadler-Williams Global Director Strategic Development and Innovation 18 th November 2015 2015 Catalent Pharma Solutions. All rights reserved
More informationASSESSMENT OF THE FUNCTIONING OF THE "CLINICAL TRIALS DIRECTIVE" 2001/20/EC PUBLIC CONSULTATION PAPER THE RESPONSE FROM UNIVERSITY COLLEGE LONDON
Joint UCLH/UCL Biomedical Research Unit Office Location: 1 st Floor Maple House 149 Tottenham Court Road London WC1 Postal Address: Rosenheim Wing, Ground Floor 25 Grafton Way London, WC1E 5DB Email:s.kerrison
More informationResponsibilities of Investigators for Clinical Trials from Consent to Safety Reporting
Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting Young-Hak Kim, MD, PhD Department of Medicine,, University of Ulsan College of Medicine, Seoul, Korea Responsibilities
More informationAbout Clinical Trials: What They Can Mean For You?
About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationVisions on the role of Statisticians in the Pharmaceutical Industry. Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S
Visions on the role of Statisticians in the Pharmaceutical Industry Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S Overview of presentation Vision & Mission A Historical view New Statistical
More informationClinical trials patient-education brochure
Released November 2005 Revised January 2008 Revised March 2012 Revised July 17, 2017 Clinical trials patient-education brochure Roslyn Mannon, MD David Rothstein, MD Maria Luisa Alegre, MD, PhD Giorgio
More informationMASTER PROTOCOLS IN COLLABORATIVE RESEARCH
MASTER PROTOCOLS IN COLLABORATIVE RESEARCH Lisa LaVange, PhD Professor and Associate Chair ASA Biopharmaceutical Section/ Industry/Regulatory Workshop Washington, DC September 13-14, 2018 Outline Precision
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More informationFirst Place Essay. Katie P.
First Place Essay Katie P. Eighth Grade West Reading, PA 19611 Bioscience research is seeking information by exploring life's processes and diseases. It has helped many scientists understand how the body
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationAndrew Finnerty General Manager - CCMI
Andrew Finnerty General Manager - CCMI Manufacturing Human Mesenchymal Stem Cells for Clinical Trials Quality Considerations Biopharma and Pharma RQA Regional Forum Bioclin Laboratories, Athlone 13 May
More informationThe Role of a Clinical Statistician in Drug Development By: Jackie Reisner
The Role of a Clinical Statistician in Drug Development By: Jackie Reisner Types of studies within clinical development Phase I Phase II Phase III Phase IV Phase I First Human Dose (FHD) Young healthy
More informationAdvanced Therapy Medicinal Products and GMP. Ashley Isbel
Advanced Therapy Medicinal Products and GMP Ashley Isbel Session Overview What are ATMPs? The State of Regulations GMP and Other Challenges for ATMP production Some Solutions The Future What are ATMPs?
More informationCTTI Overview One Decade of Impact. One Vision Ahead.
Feb. 6, 2018 CTTI Overview One Decade of Impact. One Vision Ahead. Pamela Tenaerts, MD, MBA Executive Director #CelebrateCTTI Discover how CTTI has influenced the clinical trials enterprise during the
More informationFACTS YOU NEED TO KNOW UNITED STATES OF AMERICA
CLINICAL TRIALS BROCHURE FACTS YOU NEED TO KNOW Thousands of men across the United States suffer from the difficult effects of prostate cancer and often undergo treatment that does not produce optimal
More informationThe Basis for Drug Approval in US
The Basis for Drug Approval in US Lee S. Simon, MD Associate Clinical Professor of Medicine Harvard Medical School Beth Israel Deaconess Medical Center Consulting AAI Pharma Affinergy Astrazeneca Abraxxis
More informationMoving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment Matthias Egger Mike Chambers Univ. of Berne, Switzerland GSK, UK Slide 1 Increasingly complex external
More informationRegulatory Considerations and Trends Europe and the U.S.
Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products
More informationRecruitment of Subjects Best Practices
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Recruitment of Subjects Best Practices May 2016 Objectives Definitions Goals and Barriers Recruitment
More informationMedical Affairs Not a Sunshine Day Analyzing the Impact of the Sunshine Act on Medical Affairs: Challenges for 2014 and Beyond
Medical Affairs Not a Sunshine Day Analyzing the Impact of the Sunshine Act on Medical Affairs: Challenges for 2014 and Beyond Jodi Smith, PhD and Peg Crowley Nowick, PhD, MBA Medical Affairs Not a Sunshine
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationYoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA)
-DSDQ0+/:30'$ 3HUVSHFWLYHDQG6WUDWHJ\ Yoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA) Benefit of Pharmacogenomics Improving benefit/risk ratio More safe, more effective Adjusting Dose Can determine
More informationMid-recruitment trial redesign to incorporate genetic sub-types: the PICCOLO Trial
Mid-recruitment trial redesign to incorporate genetic sub-types: the PICCOLO Trial Sarah Brown Catherine Olivier On behalf of the PICCOLO Trial Team Society for Clinical Trials May 15-18, 2011 Vancouver,
More informationAbout Clinical Trials
About Clinical Trials A guide for people with CF and their families INSIDE Who Can Participate in a Clinical Trial? Clinical Research Basics Who Is Involved in Clinical Research? Informed Consent Your
More informationWhy you Should Care about Activities Related to Clinical Trials Current Trends and Government Interest
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Why you Should Care about Activities Related to Clinical Trials Current Trends and Government Interest Craig Metz, PhD Vice President,
More informationFollowing Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls. Katie Pascoe (Value and Access, ABPI) 22 September 2016
Following Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls Katie Pascoe (Value and Access, ABPI) 22 September 2016 Partnering is a key factor in patient access to new
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationFDA Perspective on Clinical Trial Design for Rare Diseases
FDA Perspective on Clinical Trial Design for Rare Diseases American Statistical Association Biopharm Workshop Sept, 2018 Lucas Kempf, M.D. Associate Director Rare Diseases Program (acting) Office of New
More informationClinical trial design issues and options for study of rare diseases
Clinical trial design issues and options for study of rare diseases November 3, 2016 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is coordinated
More informationTalking to Active Investigators: Interview Findings
April 5, 2017 Talking to Active Investigators: Interview Findings Terri Hinkley RN, BScN, MBA, CCRC Association for Clinical Research Professionals (ACRP) Active Investigator Interviews Active Investigator:
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationSession 4: Statistical considerations in confirmatory clinical trials II
Session 4: Statistical considerations in confirmatory clinical trials II Agenda Interim analysis data monitoring committees group sequential designs Adaptive designs sample size re-estimation Phase II/III
More informationA. TRIAL IDENTIFICATION
PROTOCOL INFORMATION ON A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE CONDUCTED IN A THIRD COUNTRY (i.e. a country outside of the EEA) Note: To ensure consistency the numbering of this form is
More informationMedical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018
Medical Topics: Gene Therapy E. Anne Jackson, FSA MAAA July 30, 2018 Agenda Terminology Crash course in the science Existing FDA-approved gene therapies Underwriting implications 2 Terms related to high
More informationA SMALL FISH IN A BIG POND MATCHING THE NEEDS OF SMALLER PHARMA SPONSORS
A SMALL FISH IN A BIG POND MATCHING THE NEEDS OF SMALLER PHARMA SPONSORS WITH THE RIGHT CRO DR SALLY ADAMS DEVELOPMENT DIRECTOR SCANCELL LTD 1 SCANCELL LTD Founded in 1997 as a spin-out from the University
More informationNew Regulation for Advanced Therapies including Oncology Biological Products. isbtc Global Regulatory Summit
New Regulation for Advanced Therapies including Oncology Biological Products isbtc Global Regulatory Summit Patrick Celis, PhD European Medicines Agency (EMEA) Presentation Overview EMEA and the European
More informationMarch 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette:
March 2, 2015 The Honorable Fred Upton Chairman Energy and Commerce Committee House of Representatives Washington, DC 20515 The Honorable Frank Pallone Ranking Member Energy and Commerce Committee House
More informationINDEPENDENT CLINICAL RESEARCH: A ROAD TOWARDS AFFORDABLE & VALUABLE MEDICINES
INDEPENDENT CLINICAL RESEARCH: A ROAD TOWARDS AFFORDABLE & VALUABLE MEDICINES INTRODUCTION The current system of industry-based clinical research for new medicines is expensive and ineffective. It results
More informationFDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
More informationKey multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials
Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials Mohammad F. Huque, Ph.D. Office of Biostatistics OTS, CDER/FDA DIA Annual Meeting, Boston,
More informationMentorship in Research: It s really really important
Mentorship in Research: It s really really important Allan Garland, MD, MA Professor of Medicine & Community Health Sciences Introduction Key ingredients for a successful research career: training -- methods,
More informationGetting Published: What Journal Editors Really Want
Getting Published: What Journal Editors Really Want Edward Abraham M.D. Professor and Chair, Department of Medicine University of Alabama at Birmingham Presenter Disclosures Edward Abraham M.D. Personal
More informationDMC membership experience. P.Bauer Basel May 2016
DMC membership experience P.Bauer Basel May 2016 EMA GUIDELINE ON DATA MONITORING COMMITTEES Clinical trials frequently extend over a long period of time. Thus, for ethical reasons it is desirable to ensure
More informationList of Figures and Tables
1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 Worldwide Pharmaceutical Market Estimated Size, 2001-2008 Major World Markets Population Size and Sales Growth
More informationIntroduction to Drug Development
Introduction to Drug Development Yves Geysels, PhD Head Clinical Research Operations, Belgium Past President of the Associoation of Clinical Research Professionals (ACRP) Board Member of the European Forum
More informationRobert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation
Name and Organization: Robert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation Subject of Testimony: Food and Drug Administration Funding for Fiscal Year 2013 Point of Contact:
More informationAn exploration of the Contract Research Organisation sector in. Divya Bhagianadh
An exploration of the Contract Research Organisation sector in India Divya Bhagianadh Global scenario Outsourcing clinical trials- the new trend Estimated CRO market revenues 2000-2010e ($ bn) Total market
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public health and Risk assessment Pharmaceuticals Brussels, 01 June 2010 SANCO/C/8/SF/dn D(2010) 326199 THE RULES GOVERNING MEDICINAL PRODUCTS
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationGene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
More informationimpact on a trial design and labeling
Genotyping-impact impact on a trial design and labeling Yoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA) Benefit of Pharmacogenomics Improving benefit/risk ratio More safe, more effective Adjusting
More informationList of Figures and Tables
1.01 p. 50 1.02 p. 50 1.03 p. 51 1.04 p. 51 1.05 p. 52 1.06 p. 52 1.07 p. 53 1.08 p. 53 1.09 p. 54 1.10 p. 54 1.11 p. 55 1.12 p. 55 1.13 p. 56 1.14 p. 56 1.15 p. 57 1.16 p. 57 1.17 p. 58 1.18 p. 58 1.19
More informationLeveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions
Leveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions Author: Richard Bergstrom * Date: 14.11.2016 * Version: 1 Disruption 2 Why this discussion now Definitions.
More informationBO STO N MEDTECH. More Experience Better Results. Ethics in Clinical Research. Zvi Ladin, Ph.D.
BO STO N MEDTECH A D VI SO RS More Experience Better Results Ethics in Clinical Research Zvi Ladin, Ph.D. Historical Infamy Tuskegee syphilis study (1930s 1972) 399 black men signed with the US PHS for
More informationA Patient/Advocate Perspective
ADAPTIVE DESIGNS IN CLINICAL DRUG DEVELOPMENT : Opportunities & Challenges A Patient/Advocate Perspective Jane Perlmutter janep@gemini-grp.com May 22, 2006 Topics Advocates Who are we? What do we do? Clinical
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle (randomization) 3.4 Trial monitoring: Interim decision and group sequential designs Bios 6648- pg 1 (a) Recruitment and
More informationAssociate Group Medical Director - MD
Date: 06/11/18 Associate Group Medical Director - MD Job ID: 201805-106259 Job Function Clinical Development Location United States of America - California South San Francisco Schedule Full time Job type
More informationDesigning Generalizable Trials: Why Inclusivity Matters. Estelle Russek-Cohen, PhD U.S. Food and Drug Administration Center for Biologics
Designing Generalizable Trials: Why Inclusivity Matters Estelle Russek-Cohen, PhD U.S. Food and Drug Administration Center for Biologics 1 Disclaimer The thoughts expressed are my own and should not be
More informationOur Journey Through The Valley of Death. How Our Family Started A Virtual BioTech and Personalized Medicine Model To Save Our Twins Lives
Our Journey Through The Valley of Death How Our Family Started A Virtual BioTech and Personalized Medicine Model To Save Our Twins Lives Rare Disease Advocists Reside in Reno, Nevada Former careers in
More informationMeet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer
Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer Written by Clara Rodríguez Fernández Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing
More informationFor personal use only
23 October 2013 ANP to Present at Canary BioTech and Healthcare Investor Roadshow Antisense Therapeutics Ltd. (ASX:ANP) today announced that CEO and Managing Director, Mark Diamond, has been invited to
More informationHYPOTHETICAL SCENARIO: MINI SUMMIT II: R&D COMPLIANCE
HYPOTHETICAL SCENARIO: MINI SUMMIT II: R&D COMPLIANCE Dan Kracov, Arnold & Porter (Moderator) Sue Seferian, Johnson & Johnson Natasha Leskovsek, Cooley Michelle Shwery, Eli Lilly Pharmaceutical and Medical
More informationClinical Trials A Closer Look
The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription and over-the counter) Food Medical devices Animal feed and drugs Cosmetics
More informationHow To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup
How To Design A Clinical Trial Statistical Analysis Andrew Embleton PhD student/medical Statistician MRC Clinical Trials Unit at UCL At what points do you need to consider statistics? At what points do
More informationBIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE
1 BIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE Product Oriented Licensing Strategy intilaris LifeSciences Technologiepark Hochbergerstr. 60c CH-4057 Basel Switzerland Phone: +41 61 633 2212 Email: optimize@intilaris.com
More informationDr Amy Prosser Careers in Research: Industry
www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed
More informationUse of Real World Data in Development Programmes
Use of Real World Data in Development Programmes Dr Alison Cave and Dr Francesca Cerreta Industry Stakeholder Platform on Research and Development Support 25 April 2017 An agency of the European Union
More informationPan European Paediatric Clinical Trials Network From idea to realization
Pan European Paediatric Clinical Trials Network From idea to realization Heidrun Hildebrand, Bayer Ag Mark Turner, University of Liverpool 2 Nordic Pediatric Conference Helsinki, May 21/22, 2018 This project
More informationManaging Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD
Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationPharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
More informationPharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
More information